Edition:
United Kingdom

Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

3.16USD
26 Apr 2018
Change (% chg)

$-0.09 (-2.77%)
Prev Close
$3.25
Open
$3.25
Day's High
$3.30
Day's Low
$3.14
Volume
18,492
Avg. Vol
79,074
52-wk High
$3.96
52-wk Low
$0.78

Chart for

About

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates... (more)

Overall

Beta: 2.10
Market Cap(Mil.): $33.86
Shares Outstanding(Mil.): 24.17
Dividend: --
Yield (%): --

Financials

  APTO.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.80 -- --
ROI: -123.77 1.58 14.38
ROE: -123.77 2.41 16.07

BRIEF-Aptose Biosciences Establishes New At-The-Market Facility

* APTOSE BIOSCIENCES INC SAYS ENTERED INTO AN "AT-THE-MARKET" SALES AGREEMENT WITH CANTOR FITZGERALD & CO

28 Mar 2018

BRIEF-Aptose Reports Qtrly Loss Of $0.12‍​ Per Share

* APTOSE REPORTS RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

27 Mar 2018

BRIEF-Aptose Biosciences Announces License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology ‍​

* APTOSE BIOSCIENCES - ‍ AGREEMENT PROVIDES OHM ONCOLOGY RIGHTS FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF APL-581

07 Mar 2018

BRIEF-Aptose Biosciences Inc Files For Stock Shelf Of Upto $100 Mln

* APTOSE BIOSCIENCES INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING Source text : http://bit.ly/2BJGvqH Further company coverage:

07 Feb 2018

BRIEF-FDA Grants Orphan Drug Designation To Aptose Biosciences For CG’806 In Acute Myeloid Leukemia

* FDA GRANTS ORPHAN DRUG DESIGNATION TO APTOSE BIOSCIENCES FOR CG’806 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

26 Dec 2017

BRIEF-Aptose Biosciences Inc Q3 loss per share C$0.14

* Aptose reports results for the third quarter ended September 30, 2017

14 Nov 2017

BRIEF-Aptose enters into $15.5 mln common shares purchase agreement with Aspire Capital Fund, Llc

* Aptose enters into $15.5 million common shares purchase agreement with Aspire Capital Fund, Llc

30 Oct 2017

Earnings vs. Estimates